CereVasc has announced the publication of a case report detailing the first treatment in a study of its eShunt system—an investigational device intended to treat communicating hydrocephalus (CH).
According to a press release from the company, the eShunt device represents the first minimally invasive treatment for CH and offers the potential for significant benefits over the current treatment option regarding failure rates, infection risks, and associated costs.
The case report was authored in collaboration with Pedro Lylyk (Clínica La Sagrada Familia, Buenos Aires, Argentina), who is conducting this first-in-human study of the eShunt system at his centre, and is published in the Journal of NeuroInterventional Surgery (JNIS).
Adel Malek (Tufts Medical Center, Boston, USA), who co-authored the report and is also the co-founder of CereVasc, said: “We are very pleased to have JNIS publish the first patient case report. The details and outcome of this case are encouraging signs about the potential of the eShunt system to address a common neurological condition with a long history of poor treatment options.”
Dan Levangie, chairman and CEO of CereVasc, added: “Despite these being very early data, there is great significance in the first ever treatment of hydrocephalus using a minimally invasive approach.”
The ongoing first-in-human clinical trial, ETCHES I (Endovascular treatment of communicating hydrocephalus with the eShunt system), is evaluating the investigational device for the treatment of CH. According to CereVasc, additional study data will be available in 2022.